What's Happening?
PeproMene Bio, Inc. has announced the publication of breakthrough Phase 1 clinical trial results for its first-in-class BAFF-R-targeted CAR T-cell therapy, PMB-CT01, in The Lancet. The study evaluated PMB-CT01 in patients with relapsed or refractory B-cell
non-Hodgkin lymphoma, including those who had previously failed CD19-directed CAR T-cell therapy. The results demonstrated deep and durable complete responses (CRs) in 7 of 9 treated patients (80%), with all CRs remaining ongoing at the time of data cutoff, and the longest ongoing CR reaching 35 months. Notably, four of six patients who had progressed after conventional CD19-directed CAR T-cell therapy also achieved a complete response. PMB-CT01 exhibited a favorable safety profile, with all cytokine release syndrome (CRS) events and the two reported immune effector cell-associated neurotoxicity syndrome (ICANS) events limited to Grade 1. Based on these promising outcomes, the Phase 1 trial has expanded from a single site at City of Hope to multiple additional medical centers across the United States.
Why It's Important?
This publication marks a significant advancement in the treatment of relapsed/refractory B-cell lymphomas, particularly for patients who have exhausted other therapeutic options, including prior CD19-directed CAR T-cell therapies. The high complete response rate and the durability of these responses, coupled with an exceptionally safe profile, suggest that PMB-CT01 could be a paradigm-shifting treatment. The ability to achieve CRs in patients who failed CD19 CAR T-cell therapy is crucial, as these patients typically have very poor prognoses. The mild safety profile, with only Grade 1 CRS and ICANS events, is a notable improvement over existing CAR T-cell therapies, which often carry more severe side effects. This enhanced safety could potentially enable outpatient administration, significantly improving access to this advanced therapy for underserved patients and reducing the burden on specialized medical centers. Furthermore, targeting BAFF-R, which is essential for B-cell survival, reduces the likelihood of antigen-loss escape, a common mechanism of resistance in other CAR T-cell therapies.
What's Next?
The expansion of the Phase 1 trial to multiple medical centers across the United States indicates a rapid progression towards broader clinical development. PeproMene Bio will continue to evaluate PMB-CT01 in ongoing Phase 1 trials for relapsed/refractory B-NHL and relapsed/refractory B-ALL. The Institute for Follicular Lymphoma Innovation (IFLI) has committed up to $11 million to support the clinical development of PMB-CT01 in relapsed or refractory follicular lymphoma, further accelerating its path to market. The company will focus on gathering more data on the long-term durability and safety of PMB-CT01 across a larger patient population. If these positive results are replicated in larger trials, PMB-CT01 could move towards pivotal studies and regulatory approval, potentially becoming a new standard of care for these challenging blood cancers. The favorable safety profile also opens avenues for exploring its application in autoimmune diseases where B-cell depletion is a therapeutic strategy.
Beyond the Headlines
The success of PMB-CT01 highlights the potential of targeting novel antigens beyond CD19 in CAR T-cell therapy, offering a new strategy to overcome resistance mechanisms and improve outcomes for patients with B-cell malignancies. The exceptional safety profile observed in the trial could lead to a re-evaluation of CAR T-cell therapy administration protocols, potentially shifting from inpatient to outpatient settings. This would not only enhance patient convenience and reduce healthcare costs but also broaden the accessibility of these complex therapies. The concept of 'CAR after CAR' therapy, where a second CAR T-cell therapy targets a different antigen after failure of an initial one, represents a significant evolution in the field of cellular immunotherapy. This approach could provide a lifeline for patients who previously had no further treatment options. The potential application of BAFF-R CAR T-cell therapy in autoimmune diseases also suggests a broader therapeutic utility for this technology, extending its impact beyond oncology.
